K.S. ALTYNBEKOV

Republican Scientific-practical Center for Mental Health of the Ministry of Health of Kazakhstan, 88 Amangeldy Str., Almaty, Kazakhstan, 050022

Altynbekov K.S. ― Cand. Med. Sc., psychiatrist of Organizational-Methodological Consultancy Department, tel. (701) 775-55-13, e-mail: [email protected]

 Basing on the clinical and catamnesis data with «quality indicators», 292 case records of schizophrenic patients between 2005 and 2007 have been investigated in order to identify the significant differences in the frequency and reason of prescription of typical and atypical neuroleptics in a psychiatric hospital. During investigation, statistically significant results of higher efficiency and safety of the second generation of neuroleptics have been shown in the therapy of schizophrenic patients in the studied years.

Key words: treatment of schizophrenic patients, «quality indicators», typical neuroleptics, atypical neuroleptics, polypragmasy.

REFERENCES

1. Volkov V.P. Somatic pathology and causes of death in schizophrenia. Zhurnal nevrologii i psikhiatrii, 2009, no. 5, pp. 14-19 (in Russ.).
2. Gurovich I.Ya. Schizophrenia in the Systematics of Mental Disorders. Sotsial’naya i klinicheskaya psikhiatriya, 2014, vol. 24, iss. 2, pp. 46-49.
3. Harvey P.D. Disability in schizophrenia: contributing factors and validated assessments. J. Clin. Psychiatry, 2014, vol. 75, suppl. 1, pp. 15-20.
4. Olesen J. The economic cost of brain disorders in Europe. Eur. J. Neurol, 2012, vol. 19, suppl. 1, pp. 155-162.
5. Krasnov V.N. Psikhiatricheskaya pomoshch’ bol’nym shizofreniey. Klinicheskoe rukovodstvo [Psychiatric care for patients with schizophrenia. Clinical guidelines]. Moscow: Medpraktika, 2007. P. 260.
6. Alam D.A. The role of psychopharmacotherapy in improving the long-term outcome of schizophrenia. Essent. Psychopharmacol, 2005, vol. 6, suppl. 3, pp. 127-140.
7. Beary M. A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications. J. Psychopharmacol, 2012, vol. 26, suppl. 5, pp. 52-61.